CJEU

55 articles available

BackgroundSPCs are granted for “products”. Products are defined as active ingredients or combinations of active ingredients (Art. 1(b) SPC Regulation). But what constitutes an active ingredient? The…

On 6 March 2026, the UPC Court of Appeal in Dyson v Dreame & Eurep referred four questions concerning the extent of the UPC’s long-arm jurisdiction to the Court of Justice of the European Union –…

An offer you can refuse?The recent judgment in Teva/Cephalon firmly anchors EU jurisprudence on pay-for-delay agreements. By upholding the sanctions imposed on the two companies for a series of side…

 To ensure you don’t miss out on interesting IP law developments reported on our other blogs, we regularly provide an overview of the most-read posts from each of our IP law blogs.  With autumn now…

The withdrawal of the European Commission’s Standard Essential Patents (SEPs) Regulation proposal earlier this year has left a significant void in EU intellectual property policy. This decision was…

On 14 May, the EPO published the study Standards and the European patent system. The study seeks to improve transparency in the relationship between standards and patents in Europe, by providing…

Although the equation A + B = C seems self-evident (even for a five years old boy: remember you), the fact remains that it needed clarification by the Court of Justice of the European Union ("CJEU"),…

The eagerly awaited CJEU decision on the two joined referrals Teva v. MSD (C-119/22) and MSD v. Clonmel (C-149/22) relating to SPCs for combination products was handed down today on December 19, 2024…

The 2015 landmark decision by the Court of Justice of the European Union (CJEU) in Huawei/ZTE established a balanced framework for licensing standard essential patents (SEPs), striking a compromise…